• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Fc 介导的效应功能有助于 HIV 中和抗体的体内抗病毒作用。

Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.

机构信息

Virology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892;

Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.

出版信息

Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18754-18763. doi: 10.1073/pnas.2008236117. Epub 2020 Jul 20.

DOI:10.1073/pnas.2008236117
PMID:32690707
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7414046/
Abstract

Treatment of HIV infection with either antiretroviral (ARV) therapy or neutralizing monoclonal antibodies (NAbs) leads to a reduction in HIV plasma virus. Both ARVs and NAbs prevent new rounds of viral infection, but NAbs may have the additional capacity to accelerate the loss of virus-infected cells through Fc gamma receptor (FcγR)-mediated effector functions, which should affect the kinetics of plasma-virus decline. Here, we formally test the role of effector function in vivo by comparing the rate and timing of plasma-virus clearance in response to a single-dose treatment with either unmodified NAb or those with either reduced or augmented Fc function. When infused into viremic simian HIV (SHIV)-infected rhesus macaques, there was a 21% difference in slope of plasma-virus decline between NAb and NAb with reduced Fc function. NAb engineered to increase FcγRIII binding and improve antibody-dependent cellular cytotoxicity (ADCC) in vitro resulted in arming of effector cells in vivo, yet led to viral-decay kinetics similar to NAbs with reduced Fc function. These studies show that the predominant mechanism of antiviral activity of HIV NAbs is through inhibition of viral entry, but that Fc function can contribute to the overall antiviral activity, making them distinct from standard ARVs.

摘要

采用抗逆转录病毒(ARV)疗法或中和单克隆抗体(NAb)治疗 HIV 感染可降低 HIV 血浆病毒载量。ARV 和 NAb 均可防止新的病毒感染循环,但 NAb 可能通过 Fcγ 受体(FcγR)介导的效应功能加速感染病毒的细胞丢失,这应该会影响血浆病毒下降的动力学。在这里,我们通过比较单次剂量治疗后对未修饰的 NAb 或 Fc 功能降低或增强的 NAb 的血浆病毒清除率的速率和时间,来正式测试效应功能在体内的作用。当将其输注到携带病毒的灵长类动物 HIV(SHIV)感染的恒河猴中时,NAb 和 Fc 功能降低的 NAb 之间的血浆病毒下降斜率存在 21%的差异。在体外增加 FcγRIII 结合并改善抗体依赖性细胞毒性(ADCC)的 NAb 设计导致体内效应细胞的武装,但导致与 Fc 功能降低的 NAb 相似的病毒衰减动力学。这些研究表明,HIV NAb 的抗病毒活性的主要机制是通过抑制病毒进入,但 Fc 功能可以有助于整体抗病毒活性,使它们有别于标准的 ARV。

相似文献

1
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody.Fc 介导的效应功能有助于 HIV 中和抗体的体内抗病毒作用。
Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18754-18763. doi: 10.1073/pnas.2008236117. Epub 2020 Jul 20.
2
A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.一种抗 HIV-1 单克隆抗体 b12 的非岩藻糖基化变体在体外增强了 FcγRIIIa 介导的抗病毒活性,但不能提高对猕猴粘膜 SHIV 挑战的保护作用。
J Virol. 2012 Jun;86(11):6189-96. doi: 10.1128/JVI.00491-12. Epub 2012 Mar 28.
3
Fc receptor-mediated antiviral antibodies.Fc 受体介导的抗病毒抗体。
Curr Opin HIV AIDS. 2009 Sep;4(5):388-93. doi: 10.1097/COH.0b013e32832f0a89.
4
Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.增强抗 HIV-1 人牛嵌合广谱中和抗体的抗体依赖的细胞细胞毒性和吞噬作用。
J Virol. 2021 Jun 10;95(13):e0021921. doi: 10.1128/JVI.00219-21.
5
Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo.定量评估 Fc 介导的效应功能对体内抗 HIV-1 IgG1 抗体抗病毒活性的贡献。
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):18002-18009. doi: 10.1073/pnas.2008190117. Epub 2020 Jul 14.
6
Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis.HIV 抗体介导的吞噬作用与病毒血症降低有关,而与补体裂解增强无关。
Nat Commun. 2022 Feb 3;13(1):662. doi: 10.1038/s41467-022-28250-7.
7
Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.在人类免疫缺陷病毒1型感染的人类和猿猴-人类免疫缺陷病毒SHIVSF162P3N感染的猕猴中广泛中和抗体的产生及其通过单体gp120进行的定位
J Virol. 2016 Mar 28;90(8):4017-4031. doi: 10.1128/JVI.02898-15. Print 2016 Apr.
8
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.增强的新生儿Fc受体功能可改善对灵长类动物感染猴-人免疫缺陷病毒的保护作用。
Nature. 2014 Oct 30;514(7524):642-5. doi: 10.1038/nature13612. Epub 2014 Aug 13.
9
Potent NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein.由gp120双特异性六价广泛中和融合蛋白动员的高效自然杀伤细胞介导的HIV-1感染细胞清除。
J Virol. 2017 Sep 27;91(20). doi: 10.1128/JVI.00937-17. Print 2017 Oct 15.
10
Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques.急性 SIV 感染中被动非中和性抗体免疫对恒河猴病毒血症控制的影响有限。
PLoS One. 2013 Sep 9;8(9):e73453. doi: 10.1371/journal.pone.0073453. eCollection 2013.

引用本文的文献

1
Patrolling monocytes mediate virus neutralizing IgG effector functions: beyond neutralization capacity.巡逻单核细胞介导病毒中和IgG效应功能:超越中和能力。
Front Immunol. 2025 May 29;16:1600056. doi: 10.3389/fimmu.2025.1600056. eCollection 2025.
2
A potent and broad CD4 binding site neutralizing antibody with strong ADCC activity from a Chinese HIV-1 elite neutralizer.一名中国HIV-1精英中和者体内具有强效且广泛的CD4结合位点中和抗体及强大的ADCC活性。
Cell Discov. 2025 Jun 10;11(1):55. doi: 10.1038/s41421-025-00808-x.
3
Broadly neutralizing antibodies, nonneutralizing antibodies and broadly effector antibodies to prevent HIV transmission?用于预防HIV传播的广泛中和抗体、非中和抗体和广泛效应抗体?
AIDS. 2025 Jun 1;39(7):918-920. doi: 10.1097/QAD.0000000000004115. Epub 2025 May 8.
4
Autovaccination revisited: potential to boost antiviral immunity and facilitate HIV-1 cure/remission in children.重新审视自体疫苗接种:增强抗病毒免疫力并促进儿童HIV-1治愈/缓解的潜力。
Curr Opin HIV AIDS. 2025 May 1;20(3):271-278. doi: 10.1097/COH.0000000000000924. Epub 2025 Mar 19.
5
Engineering of CD8 T cells with an HIV-specific synthetic notch receptor to secrete broadly therapeutic antibodies for combining antiviral humoral and cellular immune responses.利用HIV特异性合成Notch受体对CD8 T细胞进行工程改造,以分泌具有广泛治疗作用的抗体,从而联合抗病毒体液免疫和细胞免疫反应。
mBio. 2025 Apr 9;16(4):e0383924. doi: 10.1128/mbio.03839-24. Epub 2025 Feb 25.
6
SIV monoclonal antibody administration spanning treatment interruption in macaques delays viral rebound and selects escape variants.在猕猴中,跨越治疗中断期给予SIV单克隆抗体可延迟病毒反弹并筛选出逃逸变体。
Proc Natl Acad Sci U S A. 2025 Feb 4;122(5):e2404767122. doi: 10.1073/pnas.2404767122. Epub 2025 Jan 30.
7
Current methods for detecting and assessing HIV-1 antibody resistance.检测和评估HIV-1抗体耐药性的当前方法。
Front Immunol. 2025 Jan 6;15:1443377. doi: 10.3389/fimmu.2024.1443377. eCollection 2024.
8
Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth.使用稳定的天然样HIV-1包膜免疫原进行的实验性医学研究可引发长期抗体反应,但缺乏中和广度。
EBioMedicine. 2025 Feb;112:105544. doi: 10.1016/j.ebiom.2024.105544. Epub 2025 Jan 2.
9
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.一项采用晚期加强剂量的同源和异源丝状病毒疫苗的1期随机试验。
NPJ Vaccines. 2024 Dec 23;9(1):255. doi: 10.1038/s41541-024-01042-4.
10
PK/PD Evaluation of Antibody-Drug Conjugates with Enhanced Immune Effector Functions.具有增强免疫效应功能的抗体药物偶联物的药代动力学/药效学评估
AAPS J. 2024 Dec 19;27(1):18. doi: 10.1208/s12248-024-00998-4.

本文引用的文献

1
Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo.定量评估 Fc 介导的效应功能对体内抗 HIV-1 IgG1 抗体抗病毒活性的贡献。
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):18002-18009. doi: 10.1073/pnas.2008190117. Epub 2020 Jul 14.
2
Dynamics of HIV DNA reservoir seeding in a cohort of superinfected Kenyan women.肯尼亚超感染女性队列中 HIV DNA 储存库播种的动力学。
PLoS Pathog. 2020 Feb 5;16(2):e1008286. doi: 10.1371/journal.ppat.1008286. eCollection 2020 Feb.
3
The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation.具有复制能力的HIV-1潜伏库主要在治疗开始时建立。
Sci Transl Med. 2019 Oct 9;11(513). doi: 10.1126/scitranslmed.aaw5589.
4
Monkeying Around: Using Non-human Primate Models to Study NK Cell Biology in HIV Infections.猴子的世界:利用非人类灵长类动物模型研究 HIV 感染中的 NK 细胞生物学。
Front Immunol. 2019 May 22;10:1124. doi: 10.3389/fimmu.2019.01124. eCollection 2019.
5
Establishment of a Novel Humanized Mouse Model To Investigate Activation and Depletion of Patient-Derived HIV Latent Reservoirs.建立一种新型人源化小鼠模型以研究患者源性 HIV 潜伏库的激活和耗竭。
J Virol. 2019 Mar 5;93(6). doi: 10.1128/JVI.02051-18. Print 2019 Mar 15.
6
Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques.Fc 依赖性功能对于抗 HIV 抗体 PGT121 在猕猴中的疗效是冗余的。
J Clin Invest. 2019 Jan 2;129(1):182-191. doi: 10.1172/JCI122466. Epub 2018 Nov 26.
7
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.在病毒血症个体中联合使用 HIV-1 广泛中和抗体的安全性和抗病毒活性。
Nat Med. 2018 Nov;24(11):1701-1707. doi: 10.1038/s41591-018-0186-4. Epub 2018 Sep 26.
8
Combination therapy with anti-HIV-1 antibodies maintains viral suppression.联合使用抗 HIV-1 抗体可维持病毒抑制。
Nature. 2018 Sep;561(7724):479-484. doi: 10.1038/s41586-018-0531-2. Epub 2018 Sep 26.
9
Rapid Sequencing of Complete Genes from Primary HIV-1 Samples.来自原发性HIV-1样本的完整基因快速测序
Virus Evol. 2016 Jul 8;2(2):vew018. doi: 10.1093/ve/vew018. eCollection 2016 Jul.
10
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.被动HIV-1抗体介导预防(AMP)概念验证疗效试验的基础与统计设计
Stat Commun Infect Dis. 2017 Jan;9(1). doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6.